Peter Heeckt
Directeur/Membre du Conseil chez Speratum Biopharma, Inc.
Profil
Peter Heeckt is currently a Director at Speratum Biopharma, Inc. He was previously a Chief Medical Officer at Smith + Nephew, Inc. and Bioventus LLC.
He obtained a doctorate degree from Ludwig-Maximilians-Universität München.
Postes actifs de Peter Heeckt
| Sociétés | Poste | Début |
|---|---|---|
Speratum Biopharma, Inc.
 Speratum Biopharma, Inc. BiotechnologyHealth Technology Speratum Biopharma, Inc. is a pre-clinical stage biotechnology company based in Dover, DE. Speratum is focused on the research and development of targeted molecular therapeutics for the treatment of cancer. The company's primary focus is developing a multi-component therapeutic against multiple cancer types that includes a proprietary RNA interference (RNAi)-inducing mimic of mir-198, a naturally occurring microRNA involved in the pathogenesis of several solid cancers, combined with a novel biocompatible material suitable for systemic and targeted delivery of nucleic acids. Speratum's platforms for drug delivery and oligonucleotide administration have broad application potential, and have been out-licensed for multiple therapeutic and research modalities. The company was founded by Christian Marín-Müller, who has been the CEO since incorporation. | Directeur/Membre du Conseil | - |
Anciens postes connus de Peter Heeckt
| Sociétés | Poste | Fin |
|---|---|---|
Bioventus LLC
 Bioventus LLC Medical SpecialtiesHealth Technology Bioventus LLC is a holding company, which manufactures medical equipment. It develops bone healing devices and distributes osteoarthritis injection therapies. Its products include ultrasound bone healing device, joint therapies, and osteoarthritis injection therapies. The company was founded in 2012 and is headquartered in Durham, NC. | Directeur Technique/Scientifique/R&D | 01/01/2018 |
Smith + Nephew, Inc.
 Smith + Nephew, Inc. Medical SpecialtiesHealth Technology Smith & Nephew, Inc. develops and markets medical devices. Its products include television cameras and monitors, endoscopes, arthroscopes, orthopedic hand owered instruments, fiber optic illumination systems, laparoscopes, and surgical instruments. The company was founded on November 27, 1975 and is headquartered in Memphis, TN. | Directeur Technique/Scientifique/R&D | - |
Formation de Peter Heeckt
| Ludwig-Maximilians-Universität München | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Bioventus LLC
Bioventus LLC Medical SpecialtiesHealth Technology Bioventus LLC is a holding company, which manufactures medical equipment. It develops bone healing devices and distributes osteoarthritis injection therapies. Its products include ultrasound bone healing device, joint therapies, and osteoarthritis injection therapies. The company was founded in 2012 and is headquartered in Durham, NC. | Health Technology |
Smith + Nephew, Inc.
Smith + Nephew, Inc. Medical SpecialtiesHealth Technology Smith & Nephew, Inc. develops and markets medical devices. Its products include television cameras and monitors, endoscopes, arthroscopes, orthopedic hand owered instruments, fiber optic illumination systems, laparoscopes, and surgical instruments. The company was founded on November 27, 1975 and is headquartered in Memphis, TN. | Health Technology |
Speratum Biopharma, Inc.
Speratum Biopharma, Inc. BiotechnologyHealth Technology Speratum Biopharma, Inc. is a pre-clinical stage biotechnology company based in Dover, DE. Speratum is focused on the research and development of targeted molecular therapeutics for the treatment of cancer. The company's primary focus is developing a multi-component therapeutic against multiple cancer types that includes a proprietary RNA interference (RNAi)-inducing mimic of mir-198, a naturally occurring microRNA involved in the pathogenesis of several solid cancers, combined with a novel biocompatible material suitable for systemic and targeted delivery of nucleic acids. Speratum's platforms for drug delivery and oligonucleotide administration have broad application potential, and have been out-licensed for multiple therapeutic and research modalities. The company was founded by Christian Marín-Müller, who has been the CEO since incorporation. | Health Technology |
